Clinical trial · Observational
Short-term Function and Pain After Treatment for Dupuytren's Disease
Comparing Short-term Function and Pain After Treatment With Collagenase Clostridium Histolyticum or Percutaneous Needle Aponeurotomy for Dupuytren's Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate short-term pain and function associated with percutaneous needle aponeurotomy (PNA) and injections of the enzyme collagenase clostridium histolyticum in patients with Dupuytren's disease. Scores on outcome measures will be compared between groups to determine whether treatments differ in terms of hand function and pain during the early post-treatment period.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dupuytren Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collagenase clostridium histolyticum | Drug | — | UNRESOLVED |
| Percutaneous Needle Aponeurotomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Percutaneous Needle Aponeurotomy
- description
- Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
- interventionNames
- Procedure: Percutaneous Needle Aponeurotomy
- label
- Xiaflex
- description
- Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
- interventionNames
- Drug: Collagenase clostridium histolyticum
Primary outcomes (21)
- measure
- Brief Michigan Hand Questionnaire (brief MHQ)
- timeFrame
- Baseline
- description
- A validated patient-reported 12-item questionnaire pertaining to several aspects of hand function that is answered on 1 through 5 Likert scales. Higher scores indicate better hand function.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult * Dupuytren's disease diagnosis * Consented to either percutaneous needle aponeurotomy or Xiaflex injection (patient choice) * Able to read/write/speak English * Must have an email address Exclusion Criteria: * Previous treatment for Dupuytren's disease * Type 2 Diabetes Mellitus * Pre-existing hand condition, previous hand surgery or trauma
References
Publications (0)
Data not yet available